Wiklund I, Berg G, Hammar M, Karlberg J, Lindgren R, Sandin K
Department of Medicine, Ostra Hospital, Göteborg, Sweden.
Maturitas. 1992 Mar;14(3):225-36. doi: 10.1016/0378-5122(92)90117-m.
The long-term effect on aspects of quality of life (QoL) of treatment with transdermal oestrogen for 2 weeks followed by transdermal oestrogen/progestogen norethisterone acetate/oestradiol TTS 0.25/0.05 mg/day for the next 2 weeks was investigated in postmenopausal women within the framework of a 1-year seven-centre trial. Of the 136 women who were included (mean age 53 +/- 4.8 years), 110 completed the study. Aspects of QoL that are of relevance in the perimenopause and postmenopause were evaluated using the Psychological General Well-Being (PGWB) index, the Women's Health Questionnaire (WHQ) and the Sleep Dysfunction Scale before and after 3 and 9 months of therapy in the oestrogen phase. Climacteric complaints were also assessed by means of the Kupperman Index. Improved well-being, i.e. less anxiety and depression, increased vitality and better self-control (P less than 0.0001) were observed, as well as reduced sleep disturbance (P less than 0.0001). The WHQ showed decreased vasomotor and somatic symptoms, and improved sex life, emotions and cognitive function (P less than 0.0001). Improvement was the same at 3 and 9 months. According to the Kupperman Index, climacteric symptoms were alleviated (P less than 0.0001). Relief of vasomotor symptoms was correlated with improvement in the WHQ (r = 0.82), the PGWB index (r = 0.58, P less than 0.0001) and sleep (r = 0.51, P less than 0.0001). Because of the absence of a placebo control group, the results must be regarded with caution until confirmed in a placebo-controlled trial.
在一项为期1年的七中心试验框架内，研究了绝经后女性接受2周经皮雌激素治疗，随后接下来2周接受经皮雌激素/醋酸炔诺酮/雌二醇透皮贴剂0.25/0.05毫克/天治疗对生活质量（QoL）各方面的长期影响。纳入的136名女性（平均年龄53±4.8岁）中，110名完成了研究。在雌激素治疗阶段的3个月和9个月治疗前后，使用心理总体幸福感（PGWB）指数、女性健康问卷（WHQ）和睡眠功能障碍量表对围绝经期和绝经后相关的生活质量方面进行了评估。还通过库珀曼指数评估了更年期症状。观察到幸福感有所改善，即焦虑和抑郁减轻、活力增加以及自我控制能力增强（P＜0.0001），同时睡眠障碍减少（P＜0.0001）。WHQ显示血管舒缩症状和躯体症状减轻，性生活、情绪和认知功能得到改善（P＜0.0001）。3个月和9个月时的改善情况相同。根据库珀曼指数，更年期症状得到缓解（P＜0.0001）。血管舒缩症状的缓解与WHQ的改善（r = 0.82）、PGWB指数的改善（r = 0.58，P＜0.0001）以及睡眠的改善（r = 0.51，P＜0.0001）相关。由于缺乏安慰剂对照组，在安慰剂对照试验得到证实之前，这些结果必须谨慎看待。
